To develop new class of oncology drugs
Respective subsidiaries of Sun Pharmaceutical Industries and the Technion – Israel institute of technology, have entered into an exclusive worldwide research and license agreement. This agreement aims at the development of a joint project, based on new findings by Nobel Prize laureate Professor Aaron Ciechanover, Dr Gila Maor and Professor Ofer Binah, that can potentially lead to the development of novel anti-cancer drugs. The pre-clinical research was funded thus far by Dr Alfred Mann.
“The Technion is delighted to partner with Sun Pharma to advance this project through pre-clinical development process. This collaboration is an excellent example of interactions between academic discovery and pharmaceutical companies demonstrating the valuable contribution academic institutions can make in bringing new products to help patients worldwide. We sincerely believe this agreement represents the beginning of a long and fruitful relationship between the Technion and Sun Pharma,” added Ciechanover and Binah.
“This collaboration is part of the various initiatives that Sun Pharma is taking to enhance its speciality pipeline. Mutually beneficial partnerships with independent research institutes, especially world renowned institutes, such as the Technion, is our preferred route to bring to the market, innovative products for unmet medical needs,” said Kirti Ganorkar, Senior Vice President, Business Development, Sun Pharma.
Comments are closed.